Nabriva Therapeutics PLC – (NASDAQ:NBRV) – Research analysts at Gabelli dropped their FY2019 earnings per share (EPS) estimates for Nabriva Therapeutics in a report issued on Wednesday, March 27th, according to Zacks Investment Research. Gabelli analyst K. Kedra now anticipates that the biotechnology company will post earnings per share of ($1.20) for the year, down from their previous forecast of ($1.15). Gabelli currently has a “Sell” rating and a $2.56 target price on the stock. Gabelli also issued estimates for Nabriva Therapeutics’ FY2022 earnings at ($0.30) EPS and FY2023 earnings at $0.00 EPS.
Nabriva Therapeutics (NASDAQ:NBRV) last released its quarterly earnings results on Tuesday, March 12th. The biotechnology company reported ($0.41) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.35) by ($0.06). Nabriva Therapeutics had a negative return on equity of 101.03% and a negative net margin of 1,188.69%. The company had revenue of $0.80 million for the quarter, compared to analysts’ expectations of $0.61 million.
Shares of NASDAQ NBRV traded up $0.06 during midday trading on Friday, reaching $2.72. 644,099 shares of the company were exchanged, compared to its average volume of 1,194,310. The company has a quick ratio of 6.11, a current ratio of 6.11 and a debt-to-equity ratio of 0.35. Nabriva Therapeutics has a 1 year low of $1.12 and a 1 year high of $6.05. The firm has a market cap of $1.90 billion, a P/E ratio of -1.67 and a beta of 2.31.
Institutional investors and hedge funds have recently made changes to their positions in the business. Jane Street Group LLC purchased a new stake in Nabriva Therapeutics in the 4th quarter valued at approximately $29,000. HRT Financial LLC acquired a new stake in shares of Nabriva Therapeutics during the 4th quarter valued at approximately $31,000. Two Sigma Advisers LP acquired a new stake in shares of Nabriva Therapeutics during the 4th quarter valued at approximately $37,000. Paloma Partners Management Co acquired a new stake in shares of Nabriva Therapeutics during the 4th quarter valued at approximately $54,000. Finally, Wedbush Securities Inc. lifted its position in shares of Nabriva Therapeutics by 12.5% during the 4th quarter. Wedbush Securities Inc. now owns 103,550 shares of the biotechnology company’s stock valued at $151,000 after acquiring an additional 11,500 shares during the period. 4.62% of the stock is currently owned by institutional investors.
About Nabriva Therapeutics
Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which is in Phase III clinical trials in intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection.
Further Reading: Balance Sheet
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.